ValuEngine downgraded shares of Mallinckrodt (NYSE:MNK) from a hold rating to a sell rating in a report issued on Monday morning, ValuEngine reports.

Other research analysts also recently issued reports about the stock. Leerink Swann set a $2.00 price target on shares of Mallinckrodt and gave the stock a hold rating in a research note on Friday, September 6th. Wells Fargo & Co decreased their price target on shares of Mallinckrodt from $25.00 to $11.00 and set a market perform rating on the stock in a research note on Thursday, June 6th. Canaccord Genuity decreased their price target on shares of Mallinckrodt from $37.00 to $22.00 and set a buy rating on the stock in a research note on Friday, June 14th. Morgan Stanley set a $5.00 price target on shares of Mallinckrodt and gave the stock a hold rating in a research note on Friday, August 9th. Finally, Mizuho decreased their price target on shares of Mallinckrodt from $22.00 to $13.00 and set a neutral rating on the stock in a research note on Tuesday, May 28th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $10.19.

MNK stock opened at $2.53 on Monday. The company has a market capitalization of $277.23 million, a PE ratio of 0.32, a price-to-earnings-growth ratio of 0.03 and a beta of 2.43. Mallinckrodt has a one year low of $1.43 and a one year high of $32.34. The company’s 50 day moving average price is $4.13 and its two-hundred day moving average price is $12.06. The company has a debt-to-equity ratio of 1.57, a quick ratio of 0.57 and a current ratio of 0.78.

Mallinckrodt (NYSE:MNK) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $2.53 EPS for the quarter, topping the consensus estimate of $2.10 by $0.43. The firm had revenue of $823.30 million for the quarter, compared to the consensus estimate of $817.55 million. Mallinckrodt had a negative net margin of 111.46% and a positive return on equity of 18.96%. The business’s revenue was down .3% compared to the same quarter last year. During the same period last year, the firm posted $2.16 earnings per share. On average, research analysts predict that Mallinckrodt will post 8.48 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Parallel Advisors LLC increased its stake in shares of Mallinckrodt by 1,239.3% in the second quarter. Parallel Advisors LLC now owns 3,000 shares of the company’s stock worth $28,000 after buying an additional 2,776 shares during the period. Coastal Capital Group Inc. purchased a new position in shares of Mallinckrodt in the second quarter worth $31,000. Anderson Fisher LLC increased its stake in shares of Mallinckrodt by 1,129.1% in the first quarter. Anderson Fisher LLC now owns 5,285 shares of the company’s stock worth $115,000 after buying an additional 4,855 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in shares of Mallinckrodt by 724.8% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 5,617 shares of the company’s stock worth $122,000 after buying an additional 4,936 shares during the period. Finally, Quantamental Technologies LLC purchased a new position in shares of Mallinckrodt in the second quarter worth $84,000.

About Mallinckrodt

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.

Featured Article: What is a dividend reinvestment plan?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.